Topical Compounded Medications for Neuropathic Pain
Yes, several topical compounded medications can be used for neuropathic pain, with the most evidence supporting lidocaine patches (5%), capsaicin (8% patches), and compounded combinations of baclofen-amitriptyline-ketamine, though the evidence for compounded formulations is limited and mixed.
Evidence-Based Topical Options
FDA-Approved Single Agents
Lidocaine 5% patches are recommended as a first-line topical agent for localized neuropathic pain, applied daily to the painful site with minimal systemic absorption 1. Up to 3 patches may be worn for 12-24 hours on affected areas 2.
Capsaicin 8% patches are strongly recommended for HIV-associated peripheral neuropathic pain and can be considered for chemotherapy-induced peripheral neuropathy (CIPN) 3, 4. A single 30-minute application can provide pain relief for at least 12 weeks, though erythema and pain are common side effects 3. Pre-treatment with 4% lidocaine for 60 minutes before capsaicin application can reduce discomfort 3.
Compounded Topical Formulations
Baclofen (10 mg) + Amitriptyline (40 mg) + Ketamine (20 mg) gel may be considered for selected patients with CIPN after discussing limited scientific evidence, potential harms, benefits, and costs 5. One trial showed improvement in CIPN symptoms, particularly on the motor subscale after 4 weeks 4. However, this combination requires compounding pharmacy preparation, is not FDA-approved, and lacks insurance reimbursement in most cases 5.
Amitriptyline (1-2%) + Ketamine (0.5-5%) compounded gel showed improvement in 75% of patients with erythromelalgia-associated neuropathic pain when applied up to 3 times daily 2. The ketamine concentration can be increased up to 5% if initial trials are ineffective 2.
Important Caveats and Contradictory Evidence
A large randomized controlled trial (n=399) found no benefit from compounded pain creams compared to placebo for neuropathic, nociceptive, or mixed pain conditions 6. The mean reduction in pain scores showed no difference between treatment and control groups (-0.1 to -0.3 points) 6. This high-quality negative trial directly contradicts smaller positive studies.
Another randomized trial (n=462) of topical ketamine 2% and amitriptyline 4% showed no benefit for CIPN 4.
Additional Topical Options with Limited Evidence
- Topical gabapentin 6% ointment has been studied but lacks strong evidence 2
- Clonidine transdermal patches (0.1-0.3 mg daily) offer weekly applications and may decrease pain through α2-adrenergic receptor agonism 2
- Diclofenac gel (1%) applied 3 times daily or diclofenac patches (180 mg once or twice daily) 1
- Topical menthol cream (1%) applied twice daily showed improvement in pain scores after 4-6 weeks in one small trial (n=51) 4
Clinical Approach
Given the conflicting evidence, topical lidocaine 5% patches and capsaicin 8% patches should be prioritized as they have FDA approval and stronger evidence 3, 4. These can be used as co-analgesics in combination with systemic medications (opioids, antidepressants, anticonvulsants) 1.
Compounded formulations should be reserved for refractory cases after FDA-approved options have failed, with explicit patient counseling about limited evidence, out-of-pocket costs, and the possibility of no benefit based on the large negative trial 5, 6.
For HIV-associated neuropathy specifically, capsaicin is strongly recommended, while gabapentin remains the first-line oral agent 3. For CIPN, duloxetine is the only strongly recommended oral medication, with topical agents serving as adjuncts 5, 4.
The heterogeneity in biomarker expression among patients suggests that lack of group benefit in trials may reflect the need for more targeted selection rather than universal inefficacy 7. However, until biomarker-directed therapy becomes clinically available, the evidence supports cautious use of compounded topicals only after standard therapies fail.